Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Common Equity (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Common Equity for 3 consecutive years, with $196.8 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 57.14% to $196.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $196.8 million through Dec 2025, up 57.14% year-over-year, with the annual reading at $196.8 million for FY2025, 57.14% up from the prior year.
  • Common Equity hit $196.8 million in Q4 2025 for Compass Therapeutics, down from $209.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $209.6 million in Q3 2025 to a low of $93.2 million in Q2 2025.
  • Historically, Common Equity has averaged $152.4 million across 3 years, with a median of $152.8 million in 2023.
  • Biggest YoY gain for Common Equity was 57.14% in 2025; the steepest drop was 36.21% in 2025.
  • Year by year, Common Equity stood at $148.5 million in 2023, then decreased by 15.69% to $125.2 million in 2024, then skyrocketed by 57.14% to $196.8 million in 2025.
  • Business Quant data shows Common Equity for CMPX at $196.8 million in Q4 2025, $209.6 million in Q3 2025, and $93.2 million in Q2 2025.